Table 2.
Effect of glycerol supplementation and L. reuteri PTA5_F13 on the metabolic activity of chicken cecal microbiota during in vitro F2
| Reactors | Mean metabolite concentration (mM) ± SD | Ratios of Total SCFAs (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acetate | Butyrate | Propionate | Succinate | Valerate | 1,3 – PDO | Total BCFAs | Total metabolites | Acetate | Butyrate | Propionate | |
| CR | |||||||||||
| Pre-treatment | 91.2 ± 0.9 | 28.8 ± 0.1 | 23.1 ± 1.0 | 7.1 ± 0.8 | 8.3 ± 0.1 | 0.0 ± 0.0 | 14.8 ± 0.2 | 174.1 ± 1.9 | 63.7 ± 0.7 | 20.1 ± 0.1 | 16.2 ± 0.7 |
| Treatment | 95.9 ± 1.0 | 27.2 ± 0.6 | 21.9 ± 0.3 | 6.8 ± 0.2 | 7.1 ± 0.1 | 0.0 ± 0.0 | 14.9 ± 0.2 | 174.0 ± 1.3 | 66.1 ± 0.2 | 15.1 ± 0.2 | 18.8 ± 0.4 |
| Treatment – Pre treatment | + 4.7 | - 1.6 | - 2.1 | - 0.3 | - 1.2 | - | + 0.1 | - 0.1 | + 2.4 | - 5.0 | + 2.6 |
| P value | 0.0036 | 0.0118 | 0.1220 | 0.6486 | 0.0002 | 0.7179 | 0.9254 | 0.0059 | 0.0041 | 0.0606 | |
| 100G | |||||||||||
| Pre-treatment | 96.2 ± 2.6 | 39.8 ± 0.9 | 14.0 ± 0.7 | 4.2 ± 0.4 | 5.7 ± 0.9 | 0.0 ± 0.0 | 13.7 ± 0.2 | 174.0 ± 1.9 | 64.1 ± 0.8 | 26.5 ± 0.5 | 9.3 ± 0.6 |
| Treatment | 61.4 ± 1.7 | 63.3 ± 0.7 | 14.7 ± 1.1 | 3.6 ± 0.2 | 4.8 ± 0.3 | 23.0 ± 1.2 | 12.1 ± 0.2 | 183.4 ± 1.8 | 44.0 ± 0.6 | 45.4 ± 0.9 | 10.6 ± 0.7 |
| Treatment – Pre treatment | - 34.8 | + 23.5 | + 0.7 | - 0.6 | - 0.9 | + 23.0 | - 1.6 | + 9.4 | - 20.1 | + 18.9 | + 1.3 |
| P value | 0.000039 | 0.000004 | 0.3918 | 0.0602 | 0.1644 | 0.000006 | 0.0004 | 0.0036 | 0.000004 | 0.000006 | 0.0915 |
| Lbr | |||||||||||
| Pre-treatment | 91.4 ± 1.5 | 32.9 ± 0.3 | 19.9 ± 0.5 | 5.9 ± 0.4 | 8.0 ± 0.2 | 0.0 ± 0.0 | 15.4 ± 0.3 | 173.6 ± 2.3 | 63.4 ± 0.3 | 22.8 ± 0.1 | 13.7 ± 0.3 |
| Treatment | 92.4 ± 1.9 | 36.1 ± 1.2 | 17.0 ± 0.3 | 4.0 ± 0.3 | 6.9 ± 0.7 | 0.0 ± 0.0 | 15.0 ± 0.6 | 171.5 ± 2.7 | 63.5 ± 0.7 | 24.7 ± 0.6 | 11.6 ± 0.4 |
| Treatment – Pre treatment | + 1.0 | + 3.2 | - 2.9 | - 1.9 | - 1.1 | - | - 0.4 | - 2.1 | + 0.1 | + 1.9 | - 2.1 |
| P value | 0.3524 | 0.0121 | 0.0007 | 0.0017 | 0.0582 | 0.4322 | 0.7846 | 0.7857 | 0.0065 | 0.0019 | |
| Lbr-100G | |||||||||||
| Pre-treatment | 89.6 ± 2.1 | 30.3 ± 0.9 | 27.1 ± 0.6 | 4.3 ± 0.5 | 5.4 ± 1.9 | 0.0 ± 0.0 | 14.9 ± 0.3 | 171.7 ± 3.1 | 60.9 ± 0.9 | 20.6 ± 0.6 | 18.5 ± 0.5 |
| Treatment | 74.0 ± 2.4 | 51.6 ± 0.2 | 22.8 ± 0.3 | 7.7 ± 0.6 | 10.4 ± 0.3 | 20.4 ± 0.3 | 13.2 ± 0.3 | 199.7 ± 3.1 | 49.9 ± 0.7 | 34.7 ± 0.6 | 15.4 ± 0.1 |
| Treatment – Pre treatment | - 15.6 | + 21.3 | - 4.3 | + 3.4 | + 5 | + 20.4 | - 1.7 | + 28.0 | - 11.0 | + 14.1 | - 3.1 |
| P value | 0.0011 | 0.000003 | 0.0004 | 0.0017 | 0.0152 | < 0.000001 | 0.0022 | 0.0003 | 0.000085 | 0.000007 | 0.0004 |
Data are means ± SD for the last 3 days of each treatment period. Delta corresponds the difference between treatment and pre-treatment. P value is calculated for the pairwise comparison of the last 3 days of treatment and pre-treatment periods within a reactor by unpaired t-test. CR, Control reactor; 100G, 100 mM glycerol; Lbr, L. reuteri PTA5_F13; Lbr-100G, L. reuteri PTA5_F13 and 100 mM glycerol